Trial Profile
Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naive Subjects With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Nov 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms Asian PREVAIL
- Sponsors Astellas Pharma
- 26 Oct 2023 Planned End Date changed from 30 Sep 2023 to 30 Jun 2024.
- 10 Apr 2022 Results published in the Advances in Therapy
- 31 Jan 2022 Planned End Date changed from 30 Sep 2022 to 30 Sep 2023.